scholarly journals Antiviral Activity and Pharmacokinetics of the HBV Capsid Assembly Modulator GLS4 in Patients with Chronic HBV Infection

2020 ◽  
Author(s):  
Hong Zhang ◽  
Fengjiao Wang ◽  
Xiaoxue Zhu ◽  
Yunfu Chen ◽  
Hong Chen ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Antiviral Activity ◽  
Accumulation Rate ◽  
Hbv Infection ◽  
Controlled Study ◽  
Core Antigen ◽  
Capsid Assembly ◽  
Chronic Hbv Infection ◽  
Chronic Hbv ◽  
The Mean

Abstract Background GLS4 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator (class I) that can inhibit HBV replication by interfering with the assembly and disassembly of HBV nucleocapsid. Here, we evaluated its antiviral activity, pharmacokinetics (PK), and tolerability in a double-blind, randomized, parallel, entecavir-controlled study. Methods Twenty four chronic HBV patients were randomized to receive a 28-day course of GLS4 (120 or 240 mg) and ritonavir (100 mg) combination (cohorts A and B, respectively) or entecavir treatment (cohort C) at a 1:1:1 ratio. Patients were followed-up for 40 days in a phase 1b study. Results The GLS4/ritonavir combination was a tolerated combination for the treatment of chronic HBV infection. A total of two, three, and three subjects presented with alanine aminotransferase flare in cohorts A, B and C, respectively. This contributed to the withdrawal of one, two, and one patient from cohorts A, B and C, respectively. The mean Ctrough of GLS4 was 205–218 ng/mL, which was approximately 3.7–3.9 times the EC90 (55.8 ng/mL), with a lower accumulation (accumulation rate: 1.1–2.0). In cohorts A, B and C, the mean declines in HBV DNA after 28 days of treatment were -1.42, -2.13, and -3.5 log10 IU/mL; in hepatitis B surface antigen were -0.06, -0.14, and -0.33 log10 IU/mL; in pregenomic RNA were -0.75, -1.78, and -0.96 log10 copies/mL; and in hepatitis B core antigen (were -0.23, -0.5, and -0.44 log10 U/mL, respectively. Conclusions Treatment with 120 mg GLS4 was tolerated and had antiviral activity in patients with chronic HBV infection.

Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection

Vaccine ◽  
2004 ◽  
Vol 22 (3-4) ◽  
pp. 439-446 ◽  
Author(s):  
Xinchun Chen ◽  
Meizhong Li ◽  
Xiaohua Le ◽  
Weimin Ma ◽  
Boping Zhou
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hbv Infection ◽  
Core Antigen ◽  
Recombinant Hepatitis ◽  
Chronic Hbv Infection ◽  
Chronic Hbv ◽  
Hepatitis B Core Antigen

scholarly journals Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

2019 ◽  
Vol 156 (5) ◽  
pp. 1392-1403.e7 ◽  
Author(s):  
Man Fung Yuen ◽  
Edward J. Gane ◽  
Dong Joon Kim ◽  
Frank Weilert ◽  
Henry Lik Yuen Chan ◽  
...  
Keyword(s):  
Antiviral Activity ◽  
Hbv Infection ◽  
Capsid Assembly ◽  
Chronic Hbv Infection ◽  
Chronic Hbv

Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection

2010 ◽  
Vol 15 (6) ◽  
pp. 887-895 ◽  
Author(s):  
Sheikh Mohammad Fazle Akbar ◽  
Osamu Yoshida ◽  
Shiyi Chen ◽  
Aguilar Julio Cesar ◽  
Masanori Abe ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Hbv Infection ◽  
Core Antigen ◽  
Chronic Hbv Infection ◽  
Immune Modulator ◽  
Chronic Hbv

scholarly journals Interleukin 21 Reinvigorates the Antiviral Activity of Hepatitis B Virus (HBV)–Specific CD8+ T Cells in Chronic HBV Infection

2018 ◽  
Vol 219 (5) ◽  
pp. 750-759 ◽  
Author(s):  
Libo Tang ◽  
Chengcong Chen ◽  
Xueping Gao ◽  
Wanyue Zhang ◽  
Xin Yan ◽  
...  
Keyword(s):  
T Cells ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Cd8 T Cells ◽  
Hbv Infection ◽  
Chronic Hbv Infection ◽  
B Virus ◽  
Chronic Hbv ◽  
Interleukin 21

Clinical-laboratory diagnostics of HBsAg-negative form of chronic HBV infection

2020 ◽  
Vol 18 (6) ◽  
pp. 138-142
Author(s):  
V. Kh. FAZYLOV ◽  
◽  
Zh. G. EREMEEVA ◽  
E. R. MANAPOVA ◽  
◽  
...  
Keyword(s):  
Hepatitis B ◽  
Clinical Laboratory ◽  
Subsequent Development ◽  
Hbv Infection ◽  
Core Antigen ◽  
Laboratory Diagnostics ◽  
Chronic Hbv Infection ◽  
Occult Hepatitis ◽  
Chronic Hbv ◽  
Negative Form

The purpose of the work is to determine the clinical and laboratory criteria for the activity of the infectious process in HBsAg-negative chronic HBV infection. Material and methods. An in-depth clinical and laboratory examination of 59 patients with the HBsAg-negative form of chronic HBV infection was carried out. According to the preliminary results of an enzyme immunoassay of blood serum, the patients had the only marker of the disease — total antibodies to the core antigen of the hepatitis B virus (anti-HBcor) in the absence of HBsAg. Traditional methods of biological statistics were used with Student’s reliability not less that 95%. Results. Comparative characteristics of the two groups based on the results of DNA detection in the polymerase chain reaction (DNA HBV+; n = 30 and DNA HBV–; n = 29) established comparability in terms of the minimum clinical picture, mainly due to concomitant pathology of the gastrointestinal tract in 40, 31% of cases, respectively; serological spectrum with the detection of total anti-HBcor in 100% of cases in the absence of HBsAg, a marker of inflammation and increased permeability of the hepatitis membrane — the activity of the enzyme alanine aminotransferase at a normal level in 65% of cases, and the absence of liver fibrosis in 89% of cases. Сonclusion. Thus, the relevance of studying HBsAg-negative (hidden, latent, occult) hepatitis B is of particular importance for the science and practice of healthcare today, as a source of infection with a risk of reactivation and subsequent development of the process with an outcome in liver cirrhosis and hepatocellular carcinoma.

scholarly journals Cango Lyec (Healing the Elephant): Chronic Hepatitis B Virus among post-conflict affected populations living in mid-Northern Uganda

PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0251573
Author(s):  
Samuel S. Malamba ◽  
Herbert Muyinda ◽  
D. Martin Ogwang ◽  
Achilles Katamba ◽  
David S. Zamar ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Hbv Infection ◽  
Core Antigen ◽  
Northern Uganda ◽  
Chronic Hbv Infection ◽  
Post Conflict ◽  
B Virus ◽  
Chronic Hbv

Background The legacy of war in Northern Uganda continues to impact people’s health and wellbeing in the Acholi region. Despite increasing attention to Hepatitis B Virus (HBV) in Uganda and globally, concerns remain that unique drivers of infection, and barriers to screening, and treatment, persist among those affected by conflict. Methods Cango Lyec (Healing the Elephant) cohort survey involved conflict-affected adults aged 13–49 in three mid-Northern Uganda districts (Gulu, Amuru and Nwoya). Baseline (2011–2012) samples were tested for HBV surface antigen (HBsAg), HBV e-antigen (HBeAg), antibodies to HBV surface antigen (HBsAb), antibodies to HBV e-antigen (HBeAb), and antibodies to HBV core antigen (HBcAb). All HBsAg positive samples were tested for IgM antibodies to HBV B core antigen (HBc-IgM) and where available, >6-month follow-up samples were tested for HBeAg and HBV DNA. Data were analyzed using STATA 15 software. Logistic regression accounted for variance due to complex two-stage sampling that included stratification, unequal selection probabilities and community clustering. Odds ratios measured effect potential risk factors associated with chronic HBV infection. Results Among 2,421 participants, 45.7% were still susceptible to HBV infection. HBsAg seropositivity was 11.9% (10.9–13.0), chronic HBV was 11.6% (10.4–12.8), acquired immunity resulting from vaccination was 10.9%, and prior natural infection was 31.5%. Older age (OR:0.570; 95%CI:0.368–0.883) and higher education (OR:0.598; 95%CI:0.412–0.868) were associated with reduced odds of chronic HBV infection. Being male (OR:1.639; 95%CI:1.007–2.669) and having been abducted (OR:1.461; 95%CI:1.055–2.023) were associated with increased odds of infection. Among women, having 1 or 2 pregnancies (compared to none or >2) was associated with increased odds of infection (OR:1.764; 95%CI:1.009–3.084). Conclusion Chronic HBV is endemic in Gulu, Amuru and Nwoya districts. Recommended strategies to reduce post-conflict prevalence include establishment of Northern Uganda Liver Wellness Centres, integration of screening and treatment into antenatal care, and roll out of birth-dose vaccination.

Sign in / Sign up

Export Citation Format

Share Document